Morningstar10d
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...
Nasdaq9d
Milestone Pharmaceuticals Reports FDA PDUFA Review Date for CARDAMYST™ Nasal Spray Targeting PSVT, Plans for Mid-2025 Launch
Milestone is also on track to initiate a Phase 3 trial for etripamil in patients with AFib-RVR in 2025. A recent investor event detailed the commercialization strategy for CARDAMYST. We have seen ...
manilatimes10d
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Milestone is on track to initiate a Phase 3 trial evaluating etripamil in AFib-RVR in 2025. The protocol of a Phase 3, potentially registrational study has been finalized and study start-up has ...